Lock-4-1-BB
/ PrecisemAb
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Tumor-localized monoclonal antibody targeting 4-1BB for superior safety and efficacy in cancer treatment
(AACR 2026)
- "These findings demonstrate that tumor-localized 4-1BB activation can uncouple efficacy from systemic toxicity. Lock-Urelumab represents a next-generation immune checkpoint agonist with strong potential to revitalize 4-1BB-targeted immunotherapy and broaden its clinical applicability."
Clinical • Oncology • CD8
1 to 1
Of
1
Go to page
1